Transplant - July 2015 Archives

Mayo Clinic part of new clinical trial to treat advanced melanoma Treating melanoma in some people can be a challenge. Now a new clinical trial ...

ROCHESTER, Minn. — Mayo Clinic is announcing results of a study on the effectiveness of left-ventricular assist devices (LVAD) in treating patients with a form of cardiomyopathy called restrictive cardiomyopathy (RCM). The Mayo Clinic study, which is the largest study of its kind to date, demonstrates that LVAD devices are a viable and accessible option for treating patients with RCM, who would otherwise see their health deteriorate or who may not survive. The study suggests criteria that clinicians can use for successful implementation of these devices in RCM. Approximately 500,000 people are currently living with cardiomyopathy, which is a condition that affects the muscles in the heart. RCM is a rare form of cardiomyopathy that limits the heart muscle from relaxing between beats when the blood returns from the body back to the heart. This causes the heart to pump weakly and restricts the flow of blood to the heart’s chambers. An LVAD is a mechanical pump that helps pump blood from the heart to the rest of the body. MEDIA CONTACT: Ginger Plumbo, Mayo Clinic Public Affairs, 507-284-5005, Email: newsbureau@mayo.edu

https://www.youtube.com/watch?v=bFLgr3G8ZQg On any given day about 15,000 Americans are on the liver transplant waiting list, hoping they can get a lifesaving donor organ in ...

ROCHESTER, Minn. — Approximately 30,000–40,000 people die from liver disease each year, according to the American Liver Foundation. For people who experience acute liver failure, ...